SCHEMBL2748423

SCHEMBL2748423

Nc1ncc(-c2cnn(CCC(=O)O)c2)cc1-c1nc2ccccc2s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 5/20 0.50
PDK2 Q15119 4/20 0.50
BTK Q06187 1/20 0.45
MAPK1 P28482 2/20 0.42
MAP4K4 O95819 1/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PI4KA P42356 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748462 0.93 MET (0.50) METPDK2BTKMAPK1MAP4K4
SCHEMBL2749424 0.90 MET (0.49) METPDK2MAPK1MAP4K4MEN1
SCHEMBL2749608 0.89 MET (0.47) METPDK2MAPK1MAP4K4MEN1
SCHEMBL2749337 0.89 BTK (0.47) METPDK2BTKMAPK1MEN1
SCHEMBL2749147 0.88 MET (0.46) METPDK2BTKMAPK1MEN1
SCHEMBL2750045 0.87 MET (0.49) METPDK2BTKMAPK1MEN1
SCHEMBL2748538 0.87 MET (0.45) METPDK2BTKMAPK1MEN1
SCHEMBL2748607 0.85 MET (0.46) METBTKMAPK1MEN1KMT2A
SCHEMBL2749719 0.85 MAPK1 (0.46) METPDK2MAPK1MAPT
SCHEMBL2750001 0.85 MET (0.46) METPDK2BTKMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 MET 38/4885PDK2 657/4885BTK 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.